Winnifred Wong, DO
Radiation Oncology · Travis Afb, CANPI 1144554148
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,702 of the $4,171 with a category attached, or 64.8%. Beigene USA, Inc. accounts for 64.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2024 at $1,957 and has fallen 67.8% since, to $631 in 2025.
Across 71 payments — averaging $58.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$3K
- AstraZeneca$203
- E.r. Squibb & Sons, L.L.C.$165
- Bristol Myers Squibb$109
- Merck$101
- Sanofi$96
- plus $795 from 21 others
What the payments were for
- Consulting fees$2,70265%
- Food & beverage$1,45735%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 3 | $2,702 |
| AstraZeneca | 10 | $203 |
| E.r. Squibb & Sons, L.L.C. | 7 | $165 |
| Bristol Myers Squibb | 4 | $109 |
| Merck | 6 | $101 |
| Sanofi | 3 | $96 |
| Novartis | 3 | $84 |
| Pfizer | 4 | $70 |
| GSK | 2 | $66 |
| Genentech USA, Inc. | 3 | $60 |
| AbbVie | 3 | $59 |
| Siemens Medical Solutions USA, Inc. | 2 | $58 |
| Incyte Corporation | 3 | $55 |
| Beone Medicines USA, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $36 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $34 |
| Johnson & Johnson | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $25 |
| Spectrum Pharmaceuticals Inc. | 1 | $25 |
| EMD Serono, Inc. | 1 | $24 |
| ADC Therapeutics America, Inc. | 1 | $21 |
| Seagen Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Amgen | 1 | $12 |
| Novocure Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$2,702
How this compares
$4,171 in reported general payments places this provider in the 80th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 29 | $742 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 32 | $265 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $121 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Travis Afb
- Rakesh PatelLos Gatos$1.3M
- Amir LavafPalm Springs$411K
- Albert ChangLos Angeles$290K
- Arya AminiDuarte$265K
- Rizwan NuraniApple Valley$220K
- Drew MoghanakiLos Angeles$183K
- Jyoti MayadevSan Diego$170K
- Percy LeeIrvine$125K
- Felix FengSan Francisco$99K
- Hyun KimDuarte$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.